Michael Buschle
Direttore/Membro del Consiglio presso VICORE PHARMA HOLDING AB
Posizioni attive di Michael Buschle
Società | Posizione | Inizio | Fine |
---|---|---|---|
VICORE PHARMA HOLDING AB | Direttore/Membro del Consiglio | 01/01/2023 | - |
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Investitore di Private Equity | 01/01/2017 | - |
Storia della carriera di Michael Buschle
Precedenti posizioni note di Michael Buschle
Società | Posizione | Inizio | Fine |
---|---|---|---|
Y-MABS THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/10/2017 | 11/12/2018 |
Independent Dir/Board Member | 01/10/2017 | 11/12/2018 | |
GLENMARK PHARMACEUTICALS LIMITED | Direttore Tecnico/Scientifico/R&S | 23/01/2012 | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Direttore Tecnico/Scientifico/R&S | 03/12/1997 | - |
Fondatore | 03/12/1997 | - |
Statistiche
Distribuzione geografica
Austria | 2 |
India | 2 |
Svizzera | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 2 |
Founder | 1 |
Settori
Health Technology | 5 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
Y-MABS THERAPEUTICS, INC. | Health Technology |
VICORE PHARMA HOLDING AB | Health Technology |
Aziende private | 2 |
---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
- Borsa valori
- Insiders
- Michael Buschle
- Esperienza